Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2

European Respiratory Journal

Volumn 24, Issue 3, 2004, Pages 353-359

  Humbert, Marc ^a   Barst, R J ^b   Robbins, I M ^c   Channick, R N ^d   Galie N ^e   Boonstra, A ^f   Rubin, L J ^d   Horn, E M ^b   Manes, A ^e   Simonneau, G ^a  

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

^b College of Physicians and Surgeons ^*  (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Bosentan; Endothelin receptors; Epoprostenol; Pulmonary arterial hypertension; Scleroderma

Indexed keywords

AMINOTRANSFERASE; BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; PLACEBO; PROSTACYCLIN; PROSTAGLANDIN DERIVATIVE;

ADOLESCENT; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BONE PAIN; CARDIOPULMONARY HEMODYNAMICS; CARDIOPULMONARY INSUFFICIENCY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DERMATITIS; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EPISTAXIS; EXERCISE; FEMALE; FLUSHING; FUNCTIONAL ASSESSMENT; HEADACHE; HEART FAILURE; HUMAN; JAW DISEASE; LEG EDEMA; LIMB PAIN; LIVER DYSFUNCTION; MALE; MORTALITY; MULTICENTER STUDY; MYALGIA; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT PARAMETERS; SIDE EFFECT; STATISTICAL SIGNIFICANCE; UPPER RESPIRATORY TRACT INFECTION;

ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EPOPROSTENOL; EXERCISE TOLERANCE; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SAFETY; SULFONAMIDES; TIME FACTORS;

EID: 4544383466     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.04.00028404     Document Type: Article

References (30)

1. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-117.
2. Stupi AM, Steen VD, Owens GR, Barnes EL, Rodnan GP, Medsger TA, Jr. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986; 29: 515-524.
3. Robbins IM, Gaine SP, Schilz R, Tapson VF, Rubin LJ, Loyd JE. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest 2000; 117: 14-18.
4. Chen YF, Oparil S. Endothelial dysfunction in the pulmonary vascular bed. Am J Med Sci 2000; 320: 223-232.
5. Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999; 159: 1925-1932.
6. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995; 333: 214-221.
7. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327: 70-75.
8. Herve P, Launay JM, Scrobohaci ML, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995; 99: 249-254.
9. Galiè N, Grigioni F, Bacchi-Reggiani L, et al. Relation of endothelin-1 to survival in patients with primary pulmonary hypertension. Eur J Clin Invest 1996; 26: Suppl. 1, 273.
10. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334: 296-302.
11. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780-788.
12. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000; 132: 425-434.
13. Humbert M, Sanchez O, Fartoukh M, et al. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study. Eur Respir J 1999; 13: 1351-1356.
14. Shapiro SM, Oudiz RJ, Cao T, et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997; 30: 343-349.
15. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106: 1477-1482.
16. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 1119-1123.
17. Badesch DB, Bodin F, Channick RN, et al. Complete results of the first randomized placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary hypertension. Curr Ther Res 2002; 63: 227-246.
18. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
19. Recommendations on the management of pulmonary hypertension in clinical practice. Heart 2001; 86: Suppl. 1, 1-13.
20. Wells AU, Hansell DM, Rubens MB, et al. Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography. Arthritis Rheum 1997; 40: 1229-1236.
21. Guyatt GH, Sullivan MJ, Thompson PJ, et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985; 132: 919-923.
22. Feinstein AR, Fisher MB, Pigeon JG. Changes in dyspnea-fatigue ratings as indicators of quality of life in the treatment of congestive heart failure. Am J Cardiol 1989; 64: 50-55.
23. Stone JH, Wigley FM. Management of systemic sclerosis: the art and science. Semin Cutan Med Surg 1998; 17: 55-64.
24. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003; 123: 344-350.
25. Jakobsen J, Glaus L, Graf P, et al. Unmasking of the hypotensive effect of nifedipine in normotensives by addition of the angiotensin converting enzyme inhibitor benazepril. J Hypertens 1992; 10: 1045-1051.
26. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349-1355.
27. Weber C, Gasser R, Hopfgartner G. Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects. Drug Metab Dispos 1999; 27: 810-815.
28. Brash AR, Jackson EK, Saggese CA, Lawson JA, Oates JA, FitzGerald GA. Metabolic disposition of prostacyclin in humans. J Pharmacol Exp Ther 1983; 226: 78-87.
29. Barst RJ, Ivy D, Dingemanse J, et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 2003; 73: 372-382.
30. Hoeper MM, Taha N, Bekjarova A, Gatzke R, Spiekerkoetter E. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur Respir J 2003; 22: 330-334.